Answers are grounded in this paper and cite their sources.
Purpose: To describe a case of bilateral diffuse uveal melanocytic proliferation in the setting of metastatic ovarian cancer. Methods: A single case was analyzed and a literature review of treatment efficacy performed. Results: A 64-year-old woman presented to ophthalmology in July 2022 for evaluation of blurred vision in the setting of ovarian cancer and a possible reaction to chemotherapy. A comprehensive workup led to the diagnosis of bilateral diffuse uveal melanocytic proliferation. Treatment to potentially preserve the patient’s vision comprised a sub-Tenon triamcinolone injection and plasmapheresis. Conclusions: Plasmapheresis did not improve the visual acuity (VA) in the patient’s right eye; however, 6 months after the last treatment, the VA in the left eye improved from 20/50 to 20/30, corresponding to a decrease in macular edema. Given the rarity of bilateral diffuse uveal melanocytic proliferation, its uncertain pathogenesis, and its varied responses to treatment, it is imperative to establish a diagnostic management and treatment algorithm to improve visual outcomes.
No takes yet. Share an insight, caveat, or question.
Olis et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: